Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Docetaxel with mFOLFOX6 for Gastric Cancer with Peritoneal Carcinomatosis
NCT04583488Phase 1Terminated
- Sponsor
- Johns Hopkins University
- Start
- Nov 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of docetaxel in gastric cancer (GC), sponsored by Johns Hopkins University. Primary endpoint: Maximum Tolerated Dose at 20 weeks. Started Nov 2020; status: terminated.
02
Drugs
docetaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04583488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04583488.